Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.47 |
| ▸ | CACNB1 | Q02641 | 4/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5080776 | 0.85 | ALOX5 (0.53) | CACNA2D1CACNA1BCACNB1CACNA1CGAA | |
| SCHEMBL8446326 | 0.82 | CACNA2D1 (0.44) | KMT2AMEN1CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL5079954 | 0.81 | KCNH2 (0.51) | KMT2ALMNAMEN1SMN1; SMN2CACNA1C | |
| SCHEMBL5024651 | 0.75 | LMNA (0.47) | POLBKMT2ALMNAMEN1SMN1; SMN2 | |
| SCHEMBL5076799 | 0.73 | KCNH2 (0.50) | KMT2ALMNAMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL13515702 | 0.73 | LMNA (0.48) | KMT2ALMNAMEN1SMN1; SMN2 | |
| SCHEMBL3038443 | 0.73 | LMNA (0.48) | KMT2ALMNAMEN1SMN1; SMN2 | |
| SCHEMBL9001323 | 0.73 | ABCB1 (0.56) | KMT2ALMNAMEN1SMN1; SMN2CACNA2D1 | |
| SCHEMBL11365566 | 0.71 | LMNA (0.78) | KMT2ALMNAMEN1SMN1; SMN2HTT | |
| SCHEMBL3042761 | 0.70 | MEN1 (0.56) | KMT2ALMNAMEN1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670775-A4 | PIPERAZINE SUBTITUTED COMPOUNDS USED AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD (CA) | 2009-04-22 | — | — | EP | claimed |
| US-7186726-B2 | Preferentially substituted calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-03-06 | — | — | US | claimed |
| JP-2007504174-A | — | — | 2007-03-01 | — | — | JP | claimed |
| EP-1670775-A1 | PIPERAZINE SUBTITUTED COMPOUNDS USED AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2006-06-21 | — | — | EP | claimed |
| WO-2005021523-A1 | PIPERAZINE SUBSTITUTED COMPOUNDS USED AS CALCIUM CHANNEL BLOCKERS | NEUROMED TECHNOLOGIES, INC. (CA) | 2005-03-10 | — | — | WO | claimed |
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-07-29 | — | — | US | claimed |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | CACNA1B, CACNA1C, CACNA1D | POLB 4151/4885KMT2A 3192/4885LMNA 2305/4885 |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | CACNA1B, TRPV1, ORAI1 | POLB 3927/4885KMT2A 4039/4885LMNA 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.